^
    8ms
    INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors (SITC 2023)
    Two of eight response evaluable pts have stable disease and remain on study (range 5+ to 10+ months). Conclusions TAC-001 appears well tolerated with dose dependent PK and PD activity consistent with the proposed proof of mechanism - evaluation & enrollment is ongoing.
    Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD22 (CD22 Molecule)
    |
    mozistobart zoratolimod (TAC-001)
    over1year
    INCLINE-101, A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in Patients with Select Advanced or Metastatic Solid Tumors (SITC 2022)
    INCLINE-101 is enrolling in the USA and Australia. Trial Registration NCT05399654
    Clinical • P1/2 data • IO biomarker
    |
    CD22 (CD22 Molecule)
    |
    mozistobart zoratolimod (TAC-001)
    3years
    [VIRTUAL] TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models (AACR 2021)
    These results demonstrate the unique properties of TAC-001 which integrates TLR9 activation and B cells to employ both innate and adaptive immune responses to promote anti-tumor activity. These data support the development of TAC-001 for a broad range of solid tumor malignancies.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL10 (Interleukin 10)
    |
    mozistobart zoratolimod (TAC-001)